Bibliographic Details
| Title: |
Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. |
| Authors: |
Pearson, Andrew D J, Rojas, Teresa de, Karres, Dominik, Reaman, Gregory, Scobie, Nicole, Fox, Elizabeth, Lesa, Giovanni, Ligas, Franca, Norga, Koen, Nysom, Karsten, Pappo, Alberto, Weigel, Brenda, Weiner, Susan L, Vassal, Gilles |
| Source: |
JNCI: Journal of the National Cancer Institute; Feb2024, Vol. 116 Issue 2, p200-207, 8p |
| Subject Terms: |
DRUG development, ANTINEOPLASTIC agents, FORUMS, PEDIATRICS, PARTICIPATION |
| Company/Entity: |
EUROPEAN Medicines Agency, UNITED States. Food & Drug Administration |
| Abstract: |
In a landscape of an increasing number of products and histology and age agnostic trials for rare patient cancer, prioritization of products is required. Paediatric Strategy Forums, organized by ACCELERATE and the European Medicines Agency with participation of the US Food and Drug Administration, are multi-stakeholder meetings that share information to best inform pediatric drug development strategies and subsequent clinical trial decisions. Academia, industry, regulators, and patient advocates are equal members, with patient advocates highlighting unmet needs of children and adolescents with cancer. The 11 Paediatric Strategy Forums since 2017 have made specific and general conclusions to accelerate drug development. Conclusions on product prioritization meetings, as well as global master protocols, have been outputs of these meetings. Forums have provided information for regulatory discussions and decisions by industry to facilitate development of high-priority products; for example, 62% of high-priority assets (agreed at a Forum) in contrast to 5% of those assets not considered high priority have been the subject of a Paediatric Investigational Plan or Written Request. Where there are multiple products of the same class, Forums have recommended a focused and sequential approach. Class prioritization resulted in an increase in waivers for non-prioritized B-cell products (44% to 75%) and a decrease in monotherapy trials, proposed in Paediatric Investigation Plans (PIP) submissions of checkpoint inhibitors from 53% to 19%. Strategy Forums could play a role in defining unmet medical needs. Multi-stakeholder forums, such as the Paediatric Strategy Forum, serve as a model to improve collaboration in the oncology drug development paradigm. [ABSTRACT FROM AUTHOR] |
|
Copyright of JNCI: Journal of the National Cancer Institute is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
